CTRI/2019/08/020588已完成未知
A Pivotal, Multiple-Dose, Pharmacokinetic Bioequivalence Trial Comparing Generic to Reference Listed Drug of Paliperidone Palmitate Extended-Release Injectable Suspension (156 mg) in Subjects with Schizophrenia or Schizoaffective Disorder
Ryan Turncliff0 个研究点目标入组 443 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 443
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1. Able to understand the investigational nature of this study and provide written informed consent prior to participation in the trial.
- •2. Male or female subjects between 18 and 65 years of age (both inclusive).
- •3. Subjects having body mass index (BMI) between 18.50 to 30.00 kg/m2 (both inclusive).
- •4. Subjects diagnosed with schizophrenia or schizoaffective disorder as per Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria
- •5. Clinically stable, defined as no psychiatric hospitalizations and no changes in any antipsychotic medication within 3 months prior to study enrollment except for the Lead-in Period
- •6. Acceptable hematology status:
- •a. Hemoglobin >= 9 g/dL
- •b. Absolute neutrophil count (ANC) >= 1500 cells/μL
- •c. Platelet count >= 100,000 cells/μLprior to dosing.
- •7. Acceptable liver function:
- •a. Alanine aminotransferase (ALT) <= 2X upper limit of normal (ULN)
- •b. Aspartate aminotransferase (AST) <= 2X ULN
- •c. Bilirubin < 1.2 mg/dL
- •d. Alkaline phosphatase <= 2X ULN
- •8. Subjects with creatinine clearance >= 80 mL/minute.
- •9. Female subjects with negative serum pregnancy test at screening.
- •10. Subjects who agree to use adequate contraception (e.g., hormonal, chemical, double-barrier, or abstinence) while in the study and for 3 months after study participation is discontinued.
- •11. Must be able to attend regularly scheduled study center appointments and be able to abide by all study requirements.
- •12. At the time of randomization, on a stable monthly dose of Paliperidone Palmitate Extended-Release Injectable Suspension, 156 mg (i.e., to have had a minimum of 2 documented monthly maintenance doses administered consecutively in the previous 2 months prior to the first study injection in the Study Treatment Period).
- •NOTE: The last monthly maintenance injection, prior to entry into the Study Treatment Period, should be administered 28 days (±1 day) prior to randomization.
- •13. Agree to receive intramuscular injections of Paliperidone Palmitate Extended-Release Injectable Suspension, 156 mg in either the deltoid or the gluteal muscle (as per randomization assignment) for the entirety of the study.
排除标准
- •1. Hypersensitivity to paliperidone palmitate or risperidone or to any of the excipients of the formulations.
- •2. Subjects who are in an acutely agitated or severely psychotic state.
- •3. Subjects who have current thoughts of suicide (suicidal ideation) or violent tendencies at the time of screening.
- •4. Subjects who have a rating of > 4 (moderately ill) on the Clinical Global Impression â?? Severity (CGI-S) scale at screening.
- •5. History or presence of neuroleptic malignant syndrome (NMS), tardive dyskinesia, dementia-related psychosis, Parkinsonâ??s disease or epilepsy/seizures.
- •6. History or presence of any uncontrolled debilitating systemic disease (e.g., cardiovascular disease, hypertension, diabetes mellitus, etc.)
- •7. History of documented addiction or substance abuse within 6 months prior to study enrollment.
- •8. Current or anticipated use during study participation of any of the prohibited medications.
- •9. Subjects with current or medical history of congenital long QT syndrome (QTc of > 470 msec for females and > 450 msec for males) or presence of severe cardiovascular disease defined as having required cardiovascular surgery or the occurrence of incapacitating myocardial infarction within past 12 months prior to study enrollment.
- •10. Subjects with history of arrhythmia.
- •11. Smokers who smoke >= 10 cigarettes or equivalent per day
- •12. Subjects with positive urine screen for drugs of abuse (except for benzodiazepines which are permissible when supported by a prescription)
- •NOTE: a positive result in the absence of a valid prescription will be discussed with the Medical Monitor before determining if the subject is to be excluded.
- •13. Major surgical procedure (including periodontal) within 28 days of first study dose of IP or planned within 9 months
- •14. Current surgical or other non-healing wounds.
- •15. Subjects with positive serology for hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).
- •16. Any other medical condition or serious intercurrent illness that, in the opinion of the Investigator, may make it undesirable for the subject to participate in the study or that could limit adherence to study requirements.
- •17. Participation in any clinical study within 90 days of IP dosing.
- •18. Donation and/or loss of >= 350 mL (1 unit) of blood within 90 days of IP dosing.
- •19. Lactating women.
研究者
相似试验
已完成
不适用
Generic drug trial seeking for approval of generic paliperidone 1 month injection for treatment of Schizophrenia.CTRI/2019/06/019832Tolmar International Ltd296
已完成
不适用
Generic drug trial to seek approval for Paliperidone 1 month injection for treatment of Schizophrenia.CTRI/2019/06/019840Tolmar International Ltd314
尚未招募
2 期
Multiple-dose pharmacokinetics and ex vivo pharmacodynamics of the fixed-dosed artemisinin based combination therapies (ACTs) of the antimalarial drugs Artequick (artemisinin-piperaquine) and Coarsucam (artesunate-amodiaquine) in healthy male Vietnamese volunteersACTRN12609000846224Australian Department of Defence44
已完成
1 期
Comparative assessment of the absorption of a generic formulation of melatonin prolonged release tablet against the innovator melatonin prolonged release tablet conducted under fasting conditions and at steady state in healthy male and female volunteersBioequivalence study conducted in healthy volunteers comparing two formulations of melatonin with no health condition or problem studied.Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, melatonin is a naturally occurring hormone produced by the pineal gland and is indicated as monotherapy for the short term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.Bioequivalence study conducted in healthy volunteers comparing two formulations of melatonin with no health condition or problem studied.Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, melatonin is a naturally occurring hormone produced by the pineal gland and is indicated as monotherapy for the short term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.Other - Research that is not of generic health relevance and not applicable to specific health categories listed aboveACTRN12615000143527Zenith Technology Corp Ltd28
已完成
1 期
Comparative assessment of the absorption of a generic formulation of quetiapine prolonged release tablet against the innovator quetiapine tablet conducted under fasting conditions and at steady state in healthy male and female volunteersBioequivalence study conducted in healthy volunteers comparing two formulations of quetiapine with no health condition or problem studied. Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, quetiapine belongs to a class of medicines called an atypical antipsychotic drug and is prescribed for the maintenance treatment of Bipolar and schizophrenia.Bioequivalence study conducted in healthy volunteers comparing two formulations of quetiapine with no health condition or problem studied.Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, quetiapine belongs to a class of medicines called an atypical antipsychotic drug and is prescribed for the maintenance treatment of Bipolar and schizophrenia.Other - Research that is not of generic health relevance and not applicable to specific health categories listed aboveACTRN12613001134718Zenith Technology Corporation Limited36